Results 241 to 250 of about 260,172 (318)
Schematic diagram showing the potential mechanism of bigelovin on the activation of NLRP3 inflammasome Bigelovin may inhibit activated protein C kinase 1 (RACK1) by directly binding with cys168 of RACK1. Bigelovin thus prevents oligomerization of NLRP3 (NLRP3 active conformation) and subsequent assembly of NLRP3 inflammasome, blocking the activation of
Jian Cui+17 more
wiley +1 more source
Editorial: Improve immunity against infection and tumor by regulating gut microbiota. [PDF]
Cai Y, Mokhtar NM, Ayerdi SGS, Kang Y.
europepmc +1 more source
In this study, Acod1 knockout in CLP mice significantly increases peripheral blood NET levels, exacerbating inflammation, organ damage, and reducing survival. Further research shows that UBR5 interacts with PAD4, a key NET formation protein. Acod1/itaconate (ITA) enhances the enzymatic activity of UBR5 by alkylating the Cys2768 site, promoting the K48 ...
Huifan Liu+10 more
wiley +1 more source
Using pet insurance claims to predict occurrence of vector-borne and zoonotic disease in humans in the United States. [PDF]
O'Brien J+3 more
europepmc +1 more source
A novel multiple cross‐linked betaine‐type amphiphilic polymer hydrogels are developed via in situ free radical copolymerization. The resultant formation, named P(SBMA‐co‐AANa) hydrogel, functions as a vitreous substitute and demonstrates superior performance in optical properties, support capacity, and biocompatibility on a vitrectomized rabbit model.
Yuting Cai+8 more
wiley +1 more source
Correlation between the interleukin-36 subfamily and gut microbiota in patients with liver cirrhosis: Implications for gut-liver axis imbalance. [PDF]
Pan YZ+9 more
europepmc +1 more source
Sympathetic nerve innervation promotes the progression of Epstein‐Barr virus‐positive diffuse large B‐cell lymphoma (EBV+ DLBCL) via β2‐adrenergic receptors. The discovery of enhanced nerve infiltration and β2AR expression reveals a novel mechanism and highlights the sympathetic–β2AR axis as a promising target for therapeutic intervention in EBV+ DLBCL.
Silan Huang+10 more
wiley +1 more source